Genmab-founder: NY is the only suitable place for biotech
A number of older, Danish biotech companies have gone public, with largely catastrophic consequences for especially former investors – but does past experience mean that the days of listing biotech companies in Denmark are over?
BY BENJAMIN WERNER CHRISTENSEN
Looking at the development in share prices, it is evident that many of the listings of Danish biotech companies formed before 2005 have been disastrous. Genmab co-founder Claus Møller has a clear idea of when it makes sense for a Danish biotech company to go public, if it finds it to be the best way to secure capital.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
“I‘m certainly not bitter, but maybe a bit disappointed”
For abonnenter
”Investors are much more cynical today”
For abonnenter
Has Danish biotech been a success?
For abonnenter
